Enzalutamide (enzalutamide) generic drug price in India

Enzalutamide (Enzalutamide) is an oral antiandrogen drug that is widely used to treat advanced prostate cancer, especially those that have metastasized. It is a type of androgen receptor inhibitor that inhibits the biological activity of androgens through multiple mechanisms, thereby inhibiting the growth and spread of prostate cancer cells.

Enzalutamide (enzalutamide) has been launched in China and has been included in medical insurance. Patients can buy it domestically at a price of about four to five thousand yuan. For specific prices and medical insurance reimbursement policies, please consult the local hospital pharmacy.

The cheaper ones abroad are mainly generic drugs. Among them, Indian generic drugs are the cheapest, about more than 2,000 yuan, which is about half of the domestic price. The ingredients of generic drugs are basically the same as those of original drugs.

Enzalutamide works by competitively binding to androgen receptors (AR ), preventing androgens from binding and activating these receptors. Under normal circumstances, androgen binding to receptors will promote the proliferation and growth of prostate cancer cells, but the binding of enzalutamide (enzalutamide) will prevent this process and inhibit tumor growth.

Enzalutamide can also inhibit the entry of androgen receptors into the nucleus and affect its binding to DNA, thereby interfering with the regulation of genes by androgen receptors. This further weakens prostate cancer cells' growth signals.

Enzalutamide also inhibits androgen synthesis, reducing the production of androgens in the body. This is particularly important for patients whose prostate cancer cells rely on androgens in the body, as it further weakens the conditions for tumor cells to grow.

Enzalutamide is often used to treat advanced prostate cancer, especially after other treatments such as hormone therapy or chemotherapy have failed. Clinical trials have shown that enzalutamide (enzalutamide) can significantly prolong progression-free survival and improve survival rates compared with traditional hormone therapy.